{"schema_version":"secwatch.filing_event.v1","accession":"0001356576-25-000004","form_type":"8-K","ticker":"SUPN","cik":"0001356576","company_name":"SUPERNUS PHARMACEUTICALS, INC.","filed_at":"2025-02-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.419817+00:00","generated_at":"2026-05-27T03:22:17.148542+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Supernus receives FDA approval for ONAPGO as first subcutaneous apomorphine infusion device for Parkinson's","bullets":["ONAPGO approved for continuous treatment of motor fluctuations in advanced Parkinson's patients not controlled by oral levodopa.","Phase 3 study: ONAPGO reduced daily OFF time by 2.6 hours vs 0.9 hours placebo (p=0.0114); GOOD ON time increased 2.8 vs 1.1 hours.","Product will be available in the U.S. in Q2 2025, with a support team including nurse education programs.","Most common adverse events (≥10%): infusion-site nodule, nausea, somnolence, infusion-site erythema, dyskinesia, headache, insomnia.","CEO Jack Khattar stated ONAPGO demonstrates Supernus' continued commitment to CNS innovation."],"urls":{"canonical":"https://secwatch.observer/filing/0001356576-25-000004","json":"https://secwatch.observer/filing/0001356576-25-000004.json","markdown":"https://secwatch.observer/filing/0001356576-25-000004.md","text":"https://secwatch.observer/filing/0001356576-25-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356576/000135657625000004/0001356576-25-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356576/000135657625000004/supn-20250204.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T03:22:17.148542+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}